Levomilnacipran

Levomilnacipran
Clinical data
Trade names	Fetzima
AHFS/Drugs.com	Monograph
MedlinePlus	a613048
License data	US DailyMed: Levomilnacipran;
Routes of; administration	By mouth
ATC code	N06AX28 (WHO) ;
Legal status
Legal status	BR: Class C1 (Other controlled substances); CA: ℞-only; US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	92%
Protein binding	22%
Metabolism	Liver (primarily by CYP3A4)
Elimination half-life	12 hours
Excretion	Kidney
Identifiers
	IUPAC name (1S,2R)-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide;
CAS Number	96847-54-0 ; HCl: 175131-60-9 ;
PubChem CID	6917779;
IUPHAR/BPS	7435;
DrugBank	DB08918;
ChemSpider	5293005 ;
UNII	UGM0326TXX; HCl: 371U2ZK31U ;
KEGG	D10072 ;
CompTox Dashboard (EPA)	DTXSID701025167 ;
Chemical and physical data
Formula	C15H22N2O
Molar mass	246.354 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(CC)C(=O)[C@]1(C[C@H]1CN)C2=CC=CC=C2;
	InChI InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m0/s1 ; Key:GJJFMKBJSRMPLA-DZGCQCFKSA-N ;
	(what is this?) (verify)

Levomilnacipran, sold under the brand name Fetzima, is an antidepressant, used for the treatment of major depressive disorder in adults. It is the levorotatory enantiomer of milnacipran, and has similar effects and pharmacology, acting as a serotonin–norepinephrine reuptake inhibitor.

Levomilnacipran was approved for medical use in the United States in July 2013.